Supernus Pharmaceuticals

Supernus Pharmaceuticals

Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

$2.5B

Market Cap • 9/22/2026

2005

(21 years)

Founded

2012

(14 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,5

P/S

3,1

P/EBITDA

P/OCF

127,7

P/FCF

135,4

P/E

BVPS

18

EPS

Market Cap

Market Cap

2,5B

EV

2,2B

EV/Revenue

2,6

EV/EBITDA

-76,5

EV/EBIT

-16,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-2%

Total Yield

-2%

Payout

0%

Retained Earnings

457,2M

Profitability

Gross Margin

88,1%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

15,2%

Capex/Revenue

0,1%

Capex/D&A

1,1%

Capex/OCF

5,6%

SBC/OCF

173,8%

% PPE

0,7%

% Goodwill

8,4%

ROE

ROIC

Growth

CAGR Revenue 5Y

7,8%

CAGR OCF 5Y

-30,2%

Leverage

N.D./EBITDA

11,9

Debt/Equity

0%

Current Ratio

2,1

Quick Ratio

1,7

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium